Clin Osteol 2013; 18(3): 77-81

Hypofosfatemická vitamín D rezistentní rachitida vázaná na X-chromozom: popis případu dvou sourozencůCase reports

P. Čamborová, V. Hůrková, L. Svitálková

Keywords: rachitida/křivice, hypofosfatemie, dědičnost, PHEX, FGF23 _ SUMMARY

Published: December 11, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čamborová P, Hůrková V, Svitálková L. Hypofosfatemická vitamín D rezistentní rachitida vázaná na X-chromozom: popis případu dvou sourozenců. Osteologický bulletin. 2013;18(3):77-81.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alizadeh Naderi AS, Reilly RF. Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol 2010;6:657. Go to original source...
    2. Shiavi SC, Kumar R. The phosphatonin pathway: New insights in phosphate ho­ meostasis. Kidney Int 2004;65:1-11. Go to original source...
    3. Meyer RA, Meyer MH, Gray RW. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia mice. J Bone Miner Res 1989;4:493-500. Go to original source...
    4. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mu­ tated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995;11:130. Go to original source...
    5. de Beur JSM, Levine MA Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab 2002;87:2467-2473. Go to original source...
    6. Ruppe MD, Brosnan PG, Au KS, Tran PX, Dominguez BW. Mutational analysis of PHEX, FGF23 and DMP1 in a kohort of patientns with hypophosphatemic ric­ kets. Clin Endocrinol 2011;74:312-318. Go to original source...
    7. Benet-Pages A, Lorenz-Depiereux B, Zischka H. FGF23 is processed by propro­ tein convertases but not by PHEX. Bone 2004;35:455. Go to original source...
    8. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y et al. FGF23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429^35. Go to original source...
    9. Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y. A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 2005;58: 329-333. Go to original source...
    10. Zivicnjak M, Schnabel D, Billing H et al. Hypophosphatemic Rickets Study Group of Arbeitsgemeinschaft fur Paediatrische Endokrinology and Gesselschaft fur Jhediatrische Nephrologie; Age-related statute and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol 2011;26: 223-231. Go to original source...
    11. Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K et al. Phenotype pre­ sentation of hypophosphatemic rickets in adults. Calcif Tissue Int 2010;87: 108-119. Go to original source...
    12. Baroncelli GI, Angiolini M, Ninni E, Galli V, Saggese R, Giuca MR. Prevalence and pathogenesis of dental an periodontal lesions in children with X-linked hy­ pophosphatemic rickets. Eur J Pediatr Dent 2006;7:61-66.
    13. Oudet C, Martin-Coigrnard D, Pannentier S, Praud E, Champion G, Hanauer A A second family with XLRH displays the mutation S244L in the CLCN5 gene. Hum Genet 1997;99:781-784. Go to original source...
    14. Carpenter TO, Imel EA, Holm IA, de Beur JSM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 2011;26:1381-1388. Go to original source...
    15. Alon US, Levy-Olomucki R, Moore WVet al. Calcimimetics as an adjuvant treat­ ment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 2008;3:658. Go to original source...
    16. Auricchio A, Sabbaht Y, Tenenhouse HS, Econs MJ. Mendelian hypophosphate­ mias. In: Scriver CR, Beaudet AL eds. The Metabolic and Molecular Bases of Inherited Diseases. New York, NY McGraw-Hill 2008; Chap. 197.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.